Physician profile
Joseph D Hoyle
NPI 1245559970
$3,338.72
in general payments reported to CMS, 2019-2025
38 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $299 · 2021: $414 · 2022: $521 · 2023: $447 · 2024: $546 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.18 | 2021-2025 | |
| Novo Nordisk INC | $613.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $288.72 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $213.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $153.83 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $141.67 | 2019-2025 | Airsupra |
| Pfizer INC. | $119.73 | 2019-2022 | |
| Astellas Pharma US INC | $116.71 | 2019-2021 | |
| Dexcom, INC. | $90.54 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $80.30 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.12 | 2022-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $67.37 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $56.49 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $55.04 | 2022-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Janssen Pharmaceuticals, INC | $52.63 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hoyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.